Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

In the phase 3 FURLONG study, the third-generation tyrosine kinase inhibitor furmonertinib significantly prolonged progression-free survival (PFS) in patients with treatment-naïve, EGFR-mutated, stage IIIB–IV non-small cell lung cancer (NSCLC), compared with gefitinib. Furmonertinib is an irreversible, selective, third-generation EGFR tyrosine kinase inhibitor. The phase 3, randomised, double-blind FURLONG study (NCT03787992) aimed to compare the efficacy and safety of furmonertinib versus gefitinib in untreated, advanced NSCLC patients with EGFR-sensitizing mutations. The trial enrolled 358 patients with treatment-naïve, stage IIIB–IV NSCLC whose tumours were EGFR mutation-positive. Patients were randomised 1:1 to receive furmonertinib 80 mg/day or gefitinib 250 mg/day first-line treatment. In the furmonertinib and gefitinib arms...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 May, 2022